ArticleBMC cancer2026
Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResearch on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited. This study aimed to evaluate whether different EGFR 19del subtypes are associated with differential clinical outcomes in patients with EGFR-mutant NSCLC receiving first-line osimertinib therapy.
methodsThis study included 106 NSCLC patients with stage IIIb–IV disease from the CAPTRA-Lung database, confirmed to have EGFR 19del mutations through next-generation sequencing (NGS) and receiving first-line osimertinib. Patients were categorized based on mutation frequencies (common E746_A750del mutation or other uncommon subtypes), the deletion start codon for the EGFR 19del (E746 or L747), and the number of deleted nucleotides (15-nucleotide deletion [15n-del] or non-15n-del). Clinical characteristics, objective response rate (ORR) and progression-free survival (PFS) were compared between these subgroups.
resultsA total of 19 EGFR 19del mutation subtypes were identified. The most frequent mutation site for exon 19 deletion was E746_A750del, accounting for 56.6% of cases (n = 60), followed by L747_P753delinsS (9.4%, n = 10), L747_T751delinsP (6.6%, n = 7), and L747_A750delinsP (4.7%, n = 5). Patients in the non-15n-del group had a higher prevalence of baseline brain metastases compared with those in the 15n-del group (41.7% vs. 22.9%; P = 0.044). No associations were found between ORR and PFS of first-line osimertinib treatment and mutation frequencies, the deletion start codon for the EGFR 19del, and the number of deleted nucleotides. However, certain subtypes, particularly L747_A750delinsP, showed a trend toward a shorter PFS compared with the common E746_A750del subtype, although these differences did not reach statistical significance (12.3 months vs. 24.3 months; P = 0.100).
conclusionsOverall, EGFR 19del subtypes showed comparable responses to first-line osimertinib. However, the trend toward poorer outcomes in the L747_A750delinsP subtype suggests potential heterogeneity that warrants confirmation in larger cohorts with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.